Breakthrough status in hand, Prosensa launches $78m IPO
This article was originally published in Scrip
Executive Summary
Taking advantage of the US FDA's decision to grant a breakthrough therapy designation for its lead drug candidate drisapersen in partnership with GlaxoSmithKline, Dutch biotechnology firm Prosensa priced its US initial public offering at $13 per share for gross proceeds of $78 million.
You may also be interested in...
IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted
Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.